Core Viewpoint - The company has received a drug registration application acceptance notice for its product, Human Coagulation Factor IX, which is aimed at treating patients with Hemophilia B and is expected to enhance its product line and core competitiveness in the long term [1][4]. Group 1: Drug Information - The drug, Human Coagulation Factor IX, is an injectable formulation with a specification of 500 IU per bottle, intended for domestic production [1]. - It is indicated for patients with congenital Factor IX deficiency or those with low Factor IX levels due to other reasons, significantly improving their Factor IX levels to prevent and treat bleeding [2]. - The company aims to develop high-recovery rate blood-derived products, addressing the long-term clinical drug shortages for Hemophilia B patients [2]. Group 2: Approval Process - The company has received the acceptance notice for the drug registration, but it still requires approval from the National Medical Products Administration before it can be marketed [3]. - The company previously announced the receipt of a clinical trial approval notice for the same drug, indicating progress in the regulatory process [3]. Group 3: Impact on the Company - The receipt of the drug registration acceptance notice will not impact the company's current performance but is expected to enrich its product line and optimize product structure in the long term [4]. - This development is anticipated to enhance the comprehensive utilization rate of raw plasma and improve profitability, thereby strengthening the company's core competitiveness [4].

Core Viewpoint - Palin Biopharma (000403) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the approval notice for the marketing registration of human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approved drug, human coagulation factor IX, is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug is expected to significantly increase the levels of human coagulation factor IX in the blood, thereby achieving the goal of preventing and treating bleeding [1]

Core Viewpoint - The company, Palin Bio (000403.SZ), announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approval signifies a significant milestone for the company in the biopharmaceutical sector [1] - The drug is expected to enhance the company's product portfolio and market presence in the coagulation factor segment [1] - This development may lead to potential revenue growth and increased investor interest in the company [1]

Core Viewpoint - The company, Palin Bio (000403.SZ), announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The approval signifies a significant milestone for the company in the biopharmaceutical sector [1] - The drug is expected to enhance the company's product portfolio and market presence in the coagulation therapy segment [1]

Core Viewpoint - Palin Bio (000403.SZ) announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received the acceptance notice for the drug registration and marketing license for human coagulation factor IX from the National Medical Products Administration [1] Group 1 - The human coagulation factor IX is indicated for the treatment of patients with congenital factor IX deficiency, specifically those with hemophilia B, or patients with low levels of factor IX due to other reasons [1] - The drug significantly enhances the levels of human coagulation factor IX in the blood, thereby preventing and treating bleeding [1] - Hemophilia B is classified as a rare disease, and there is a long-term shortage of clinical medications, with existing treatments having room for improvement in active recovery rates [1] Group 2 - The company is committed to patient-centered approaches and aims to develop blood-derived drugs with high recovery rates [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the drug registration approval notice from the National Medical Products Administration for human coagulation factor IX, which is intended for treating patients with hemophilia B due to congenital factor IX deficiency or other causes of low factor IX levels [1] Group 1 - The drug is indicated for patients with congenital hemophilia B or those with low levels of human coagulation factor IX due to other reasons [1] - The treatment aims to significantly increase the levels of human coagulation factor IX in the blood, thereby preventing and treating bleeding episodes [1]

Core Viewpoint - The company has decided to terminate the development of prothrombin complex concentrate and shift focus to the more advantageous development of human coagulation factor IX, due to market demand, competitive landscape, and cost-effectiveness considerations [1][2]. Market Demand and Competitive Landscape - The domestic market for prothrombin complex concentrate has seen stable issuance volumes with limited new market space, while the market for human factor IX has fewer competitors and significant growth potential [1]. - Human factor IX is considered a better option for treating hemophilia B due to its lower risk of thrombotic side effects compared to prothrombin complex concentrate [1][2]. Product Comparison Analysis - Prothrombin complex concentrate contains various vitamin K-dependent factors and may pose risks of thrombosis with repeated high-dose use, while human factor IX is purer and has a higher specific activity, making it a safer treatment option [1][2]. Cost-Effectiveness Analysis - The clinical trial approval for prothrombin complex concentrate was obtained in 2008, but the regulatory requirements for production site changes and the need for extensive research have made it less economically viable compared to human factor IX, which has a higher sales price and greater market growth potential [2][4]. Project Background and Investment Plan - The genomic DNA length of human factor IX is approximately 34,000 bp, and the project is expected to complete development and obtain production approval by the end of 2030 [2][4]. - The estimated investment for the development of human factor IX is 60 million yuan, with funding sourced from both raised capital and the company's own funds [4]. Project Benefits and Feasibility - The human factor IX product is aimed at treating patients with factor IX deficiency (hemophilia B), and the limited number of competitors in this market suggests significant future growth opportunities [5]. - The project aligns with market trends and the company's operational needs, enhancing resource allocation and economic benefits, thereby improving profitability and market competitiveness [5][7]. Implementation Timeline - The implementation timeline for the new product development is expected to be completed by the end of 2030, with the associated production line construction already finished [6][4]. Impact of Changes on the Company - The termination of the prothrombin complex concentrate project will reduce the current year's net profit but is expected to enhance the company's future product development and sales capabilities [7]. - The board and supervisory committee have approved the change in fundraising purposes, emphasizing the alignment with the company's operational needs and long-term interests [8][10].

Core Viewpoint - The company has announced changes regarding its financial reporting and the use of raised funds, including the appointment of new auditors and the reallocation of surplus funds to enhance operational efficiency [6][34][46]. Financial Reporting - The board and management have confirmed the accuracy and completeness of the quarterly report, which has not been audited [2][3]. - The company has not made any retrospective adjustments or restatements to previous accounting data [3]. Auditor Changes - The company has appointed new signing auditors from KPMG Huazhen due to internal adjustments, with the new auditors being Wang Pu and Li Bingman [6][7]. Shareholder Meeting - The company will hold its third extraordinary general meeting on November 13, 2025, to discuss various proposals, including the reallocation of surplus funds [12][13][14]. Fund Utilization - The company plans to permanently supplement its working capital with surplus funds from completed projects, totaling approximately 27.62 million yuan [34][39]. - The surplus funds are primarily due to lower-than-expected transaction costs and effective cash management [37][38]. Project Changes - The company has revised the use of raised funds for new product development, shifting focus from the development of prothrombin complex to factor IX, while maintaining the overall budget for the project at 340.5 million yuan [46][47].